Clinical trials: Female Breast Neoplasms
Bone Density
ATAC - Bone Density Sub-Protocol
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.
- Trial name
- NCT00784940
- Testing
- Anastrozole, Tamoxifen
- Volunteers
- 308 people
- Sponsor
- AstraZeneca
Hereditary Breast and Ovarian Cancer Syndrome
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
The purpose of this study is to determine proportion of patients presented a search allelic imbalance of expression of genes BRCA 1 and 2 in population with hereditary breast and/or ovarian cancer risk and negative for deletion…
- Trial name
- EXSAL (NCT01333748)
- Testing
- blood collection
- Where
- 6 sites in France
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
HER2-positive Breast Cancer, Recurrent Breast Cancer
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
This phase I trial studies the safety and the ability to expand laboratory-treated T cells when given together with cyclophosphamide or denileukin diftitox in treating patients with human epidermal growth factor receptor…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00228358
- Testing
- ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Breast Cancer Risk
FH-Risk 2.0: Updating Breast Cancer Risk Estimates
In the UK women with a strong family history of breast cancer are eligible for breast cancer risk estimation via Family History Risk and Prevention Clinics (FHRPCs).
- Trial name
- NCT05082740
- Testing
- Notification of a revised breast cancer risk estimate
- Where
- United Kingdom
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Recurrent Breast Cancer, Stage IV Breast Cancer
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
This phase II trial is studying how well giving capecitabine together with tipifarnib works in treating women with taxane-resistant metastatic breast cancer.
- Trial name
- NCT00077363
- Testing
- tipifarnib, capecitabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Upper Extremity Dysfunction
Reliability And Validity Study Of "The Evaluation Tool For Myofascial Adhesions In Patients After Breast Cancer" In Turkish Language
The aim of this observational study is to translate the MAP-BC Evaluation Tool into Turkish by adapting it to Turkish society and to conduct a validity and reliability study in women who have received breast cancer treatment.
- Conditions
- Breast Cancer, Upper Extremity Dysfunction, Tissue Adhesion
- Trial name
- MAP-BC (NCT05923164)
- Testing
- MAP-BC (Myofascial Adhesions in Patients after Breast Cancer) Evaluation Tool, Patient And Observer Scar Assessment Scale ( Observer Subscale)
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Breast Cancer
Nurse-Delivered Adapted MBSR During Breast Cancer Radiotherapy
This randomized study examined whether adding a condensed mindfulness programme to standard radiotherapy care could improve psychosocial outcomes among women treated for breast cancer.
- Trial name
- NCT06025799
- Testing
- Adapted mindfulness-based stress reduction
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Ovarian Cancer, Breast Cancer
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced…
- Conditions
- Ovarian Cancer, Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer
- Trial name
- LNCB74-01 (NCT06774963)
- Testing
- LNCB74
- Where
- 17 sites in United States
- Volunteers
- 145 people
- Sponsor
- LigaChem Biosciences, Inc.
Breast Cancer Females, Breast Reconstruction
Influencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer
The aim of this study is to evaluate the aesthetic outcomes in immediate implant-based breast reconstruction following breast mastectomy surgery.
- Trial name
- NCT07419971
- Testing
- synthetic mesh
- Where
- China
- Volunteers
- 300 people
- Sponsor
- West China Hospital
Breast Cancer
Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. 4-hydroxytamoxifen gel (a substance made when tamoxifen breaks down in the body) may be effective in…
- Trial name
- NCT00084344
- Testing
- 4-hydroxytamoxifen, breast imaging study, radiomammography
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Cancer Female
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharmacokinetic (PK)-adjusted docetaxel.
- Trial name
- NCT02502864
- Testing
- Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Breast Cancer Female
SNAPS Breast Cancer Patient Study Breast Cancer Patients
Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states.
- Trial name
- NCT05370300
- Testing
- Blood test
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Immunis.AI
Breast Cancer
Nutrition Intervention in Treating Women With Breast Cancer
RATIONALE: Dietary fat may be involved in the growth of cancer cells. Restricting dietary fat may help fight cancer. PURPOSE: Randomized clinical trial to study the effectiveness of a low fat diet in treating postmenopausal women…
- Trial name
- NCT00002564
- Testing
- educational intervention, therapeutic dietary intervention
- Where
- 37 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Institute for Cancer Prevention (IFCP)
Ovarian Cancer, Breast Cancer
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy.
- Trial name
- NCT04041128
- Testing
- Lynparza
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002628
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Louis University
Breast Cancer
Hormone Therapy in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using arzoxifene hydrochloride may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003428
- Testing
- arzoxifene hydrochloride
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.
- Trial name
- NCT02538484
- Testing
- Letrozole, Fish Oil
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Breast Cancer
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00066378
- Testing
- anastrozole, gefitinib
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.